How do we manage cardiopulmonary bypass coagulopathy?

Kerry J. Welsh, Elena Nedelcu, Yu Bai, Amer Wahed, Kimberly Klein, Hlaing Tint, Igor Gregoric, Manish Patel, Biswajit Kar, Pranav Loyalka, Sriram Nathan, Paul Loubser, Phillip A. Weeks, Rajko Radovancevic, Andy N D Nguyen

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

BACKGROUND: Patients who undergo cardiopulmonary bypass (CPB) are at risk for coagulopathy. Suboptimal turnaround time (TAT) of laboratory coagulation testing results in empiric administration of blood products to treat massive bleeding. We describe our initiative in establishing the coagulation-based hemotherapy (CBH) service, a clinical pathology consultation service that uses rapid TAT coagulation testing and provides comprehensive assessment of bleeding in patients undergoing CPB. A transfusion algorithm that treats the underlying cause of coagulopathy was developed. STUDY DESIGN AND METHODS: The coagulation testing menu includes all aspects of coagulopathy with close proximity of the laboratory to the operating room to allow for rapid test results. The hemotherapy pathologist monitors laboratory results at several stages in surgery and uses a comprehensive algorithm to monitor a patient's hemostasis. The optimal number and type of blood products are selected when the patient is taken off CPB. RESULTS: The CBH service was consulted for 44 ventricular assist device implants, 30 heart transplants, and 31 other cardiovascular surgeries from May 2012 through November 2013. The TAT for laboratory tests was 15 minutes for complete blood count, antithrombin, and coagulation panel and 30 minutes for VerifyNow and thromboelastography, in comparison to 45 to 60 minutes in normal settings. The transfusion algorithms were used with optimal administration of blood components with preliminary data suggestive of reduced blood product usage and better patient outcomes. CONCLUSION: We described the successful introduction of a novel pathology consultation service that uses a rapid TAT coagulation testing menu with transfusion algorithms for improved management of CPB patients.

Original languageEnglish (US)
Pages (from-to)2158-2166
Number of pages9
JournalTransfusion
Volume54
Issue number9
DOIs
StatePublished - 2014
Externally publishedYes

Fingerprint

Cardiopulmonary Bypass
Referral and Consultation
Hemorrhage
Thrombelastography
Heart-Assist Devices
Clinical Pathology
Antithrombins
Blood Cell Count
Operating Rooms
Hemostasis
Pathology
Transplants

ASJC Scopus subject areas

  • Hematology
  • Immunology
  • Immunology and Allergy
  • Medicine(all)

Cite this

Welsh, K. J., Nedelcu, E., Bai, Y., Wahed, A., Klein, K., Tint, H., ... Nguyen, A. N. D. (2014). How do we manage cardiopulmonary bypass coagulopathy? Transfusion, 54(9), 2158-2166. https://doi.org/10.1111/trf.12751

How do we manage cardiopulmonary bypass coagulopathy? / Welsh, Kerry J.; Nedelcu, Elena; Bai, Yu; Wahed, Amer; Klein, Kimberly; Tint, Hlaing; Gregoric, Igor; Patel, Manish; Kar, Biswajit; Loyalka, Pranav; Nathan, Sriram; Loubser, Paul; Weeks, Phillip A.; Radovancevic, Rajko; Nguyen, Andy N D.

In: Transfusion, Vol. 54, No. 9, 2014, p. 2158-2166.

Research output: Contribution to journalArticle

Welsh, KJ, Nedelcu, E, Bai, Y, Wahed, A, Klein, K, Tint, H, Gregoric, I, Patel, M, Kar, B, Loyalka, P, Nathan, S, Loubser, P, Weeks, PA, Radovancevic, R & Nguyen, AND 2014, 'How do we manage cardiopulmonary bypass coagulopathy?', Transfusion, vol. 54, no. 9, pp. 2158-2166. https://doi.org/10.1111/trf.12751
Welsh KJ, Nedelcu E, Bai Y, Wahed A, Klein K, Tint H et al. How do we manage cardiopulmonary bypass coagulopathy? Transfusion. 2014;54(9):2158-2166. https://doi.org/10.1111/trf.12751
Welsh, Kerry J. ; Nedelcu, Elena ; Bai, Yu ; Wahed, Amer ; Klein, Kimberly ; Tint, Hlaing ; Gregoric, Igor ; Patel, Manish ; Kar, Biswajit ; Loyalka, Pranav ; Nathan, Sriram ; Loubser, Paul ; Weeks, Phillip A. ; Radovancevic, Rajko ; Nguyen, Andy N D. / How do we manage cardiopulmonary bypass coagulopathy?. In: Transfusion. 2014 ; Vol. 54, No. 9. pp. 2158-2166.
@article{dc97369fe3a6417abff471fe46ab2e72,
title = "How do we manage cardiopulmonary bypass coagulopathy?",
abstract = "BACKGROUND: Patients who undergo cardiopulmonary bypass (CPB) are at risk for coagulopathy. Suboptimal turnaround time (TAT) of laboratory coagulation testing results in empiric administration of blood products to treat massive bleeding. We describe our initiative in establishing the coagulation-based hemotherapy (CBH) service, a clinical pathology consultation service that uses rapid TAT coagulation testing and provides comprehensive assessment of bleeding in patients undergoing CPB. A transfusion algorithm that treats the underlying cause of coagulopathy was developed. STUDY DESIGN AND METHODS: The coagulation testing menu includes all aspects of coagulopathy with close proximity of the laboratory to the operating room to allow for rapid test results. The hemotherapy pathologist monitors laboratory results at several stages in surgery and uses a comprehensive algorithm to monitor a patient's hemostasis. The optimal number and type of blood products are selected when the patient is taken off CPB. RESULTS: The CBH service was consulted for 44 ventricular assist device implants, 30 heart transplants, and 31 other cardiovascular surgeries from May 2012 through November 2013. The TAT for laboratory tests was 15 minutes for complete blood count, antithrombin, and coagulation panel and 30 minutes for VerifyNow and thromboelastography, in comparison to 45 to 60 minutes in normal settings. The transfusion algorithms were used with optimal administration of blood components with preliminary data suggestive of reduced blood product usage and better patient outcomes. CONCLUSION: We described the successful introduction of a novel pathology consultation service that uses a rapid TAT coagulation testing menu with transfusion algorithms for improved management of CPB patients.",
author = "Welsh, {Kerry J.} and Elena Nedelcu and Yu Bai and Amer Wahed and Kimberly Klein and Hlaing Tint and Igor Gregoric and Manish Patel and Biswajit Kar and Pranav Loyalka and Sriram Nathan and Paul Loubser and Weeks, {Phillip A.} and Rajko Radovancevic and Nguyen, {Andy N D}",
year = "2014",
doi = "10.1111/trf.12751",
language = "English (US)",
volume = "54",
pages = "2158--2166",
journal = "Transfusion",
issn = "0041-1132",
publisher = "Wiley-Blackwell",
number = "9",

}

TY - JOUR

T1 - How do we manage cardiopulmonary bypass coagulopathy?

AU - Welsh, Kerry J.

AU - Nedelcu, Elena

AU - Bai, Yu

AU - Wahed, Amer

AU - Klein, Kimberly

AU - Tint, Hlaing

AU - Gregoric, Igor

AU - Patel, Manish

AU - Kar, Biswajit

AU - Loyalka, Pranav

AU - Nathan, Sriram

AU - Loubser, Paul

AU - Weeks, Phillip A.

AU - Radovancevic, Rajko

AU - Nguyen, Andy N D

PY - 2014

Y1 - 2014

N2 - BACKGROUND: Patients who undergo cardiopulmonary bypass (CPB) are at risk for coagulopathy. Suboptimal turnaround time (TAT) of laboratory coagulation testing results in empiric administration of blood products to treat massive bleeding. We describe our initiative in establishing the coagulation-based hemotherapy (CBH) service, a clinical pathology consultation service that uses rapid TAT coagulation testing and provides comprehensive assessment of bleeding in patients undergoing CPB. A transfusion algorithm that treats the underlying cause of coagulopathy was developed. STUDY DESIGN AND METHODS: The coagulation testing menu includes all aspects of coagulopathy with close proximity of the laboratory to the operating room to allow for rapid test results. The hemotherapy pathologist monitors laboratory results at several stages in surgery and uses a comprehensive algorithm to monitor a patient's hemostasis. The optimal number and type of blood products are selected when the patient is taken off CPB. RESULTS: The CBH service was consulted for 44 ventricular assist device implants, 30 heart transplants, and 31 other cardiovascular surgeries from May 2012 through November 2013. The TAT for laboratory tests was 15 minutes for complete blood count, antithrombin, and coagulation panel and 30 minutes for VerifyNow and thromboelastography, in comparison to 45 to 60 minutes in normal settings. The transfusion algorithms were used with optimal administration of blood components with preliminary data suggestive of reduced blood product usage and better patient outcomes. CONCLUSION: We described the successful introduction of a novel pathology consultation service that uses a rapid TAT coagulation testing menu with transfusion algorithms for improved management of CPB patients.

AB - BACKGROUND: Patients who undergo cardiopulmonary bypass (CPB) are at risk for coagulopathy. Suboptimal turnaround time (TAT) of laboratory coagulation testing results in empiric administration of blood products to treat massive bleeding. We describe our initiative in establishing the coagulation-based hemotherapy (CBH) service, a clinical pathology consultation service that uses rapid TAT coagulation testing and provides comprehensive assessment of bleeding in patients undergoing CPB. A transfusion algorithm that treats the underlying cause of coagulopathy was developed. STUDY DESIGN AND METHODS: The coagulation testing menu includes all aspects of coagulopathy with close proximity of the laboratory to the operating room to allow for rapid test results. The hemotherapy pathologist monitors laboratory results at several stages in surgery and uses a comprehensive algorithm to monitor a patient's hemostasis. The optimal number and type of blood products are selected when the patient is taken off CPB. RESULTS: The CBH service was consulted for 44 ventricular assist device implants, 30 heart transplants, and 31 other cardiovascular surgeries from May 2012 through November 2013. The TAT for laboratory tests was 15 minutes for complete blood count, antithrombin, and coagulation panel and 30 minutes for VerifyNow and thromboelastography, in comparison to 45 to 60 minutes in normal settings. The transfusion algorithms were used with optimal administration of blood components with preliminary data suggestive of reduced blood product usage and better patient outcomes. CONCLUSION: We described the successful introduction of a novel pathology consultation service that uses a rapid TAT coagulation testing menu with transfusion algorithms for improved management of CPB patients.

UR - http://www.scopus.com/inward/record.url?scp=84908204596&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84908204596&partnerID=8YFLogxK

U2 - 10.1111/trf.12751

DO - 10.1111/trf.12751

M3 - Article

C2 - 24942083

AN - SCOPUS:84908204596

VL - 54

SP - 2158

EP - 2166

JO - Transfusion

JF - Transfusion

SN - 0041-1132

IS - 9

ER -